Prestige Consumer Healthcare Acquires Breathe Right Leader

Prestige Consumer Healthcare (PBH) has announced a definitive agreement to acquire the Breathe Right® nasal strip brand from Foundation Consumer Healthcare. Breathe Right is the clear market leader in its category, a position it has held for decades. The transaction is valued at approximately $170 million, which represents an 11.0x multiple of the brand's EBITDA.

The company plans to finance the purchase using its existing cash reserves and a new Term Loan credit facility. This structure allows Prestige to leverage its strong balance sheet to fund growth. The deal is not yet final and is subject to standard closing conditions, including regulatory approval under antitrust laws, with an expected completion date in the first half of fiscal 2027.

For Prestige, this acquisition fits squarely within its stated strategy of pursuing disciplined mergers and acquisitions. The company has a history of acquiring established, trusted consumer healthcare brands and integrating them efficiently into its portfolio. Advisors on the deal include major financial and legal firms, with Citi advising Prestige and Canaccord Genuity advising the seller.

Breathe Right is a household name, primarily used by consumers to relieve nasal congestion and reduce snoring by physically opening nasal passages. The brand commands significant shelf space in drugstores, grocery stores, and mass retailers across North America and other key markets.

This acquisition matters because it immediately strengthens Prestige's financial profile. Management expects the deal to be accretive to gross margins, EBITDA margins, and earnings per share (EPS) right out of the gate. Adding a high-margin, market-leading brand boosts the overall profitability of Prestige's brand portfolio.

Strategically, it allows Prestige to enter two attractive and growing consumer health categories: sleep support and better breathing. This diversifies the company's revenue streams beyond its core areas like over-the-counter analgesics and gastrointestinal remedies. It's a logical expansion into adjacent wellness spaces where consumers are increasingly spending money.

The 11.0x EBITDA purchase price is viewed as reasonable for a market-leading brand with strong cash flow. Importantly, Prestige has outlined a clear path to rapidly pay down the debt from this deal. The company targets reducing its leverage ratio to below 3.0x by fiscal 2028, which would return it to a very comfortable financial position post-acquisition.

For investors, this move signals that Prestige's management is actively executing its growth plan and can deploy capital effectively. A successful integration of Breathe Right would demonstrate the company's operational prowess and could build confidence in its ability to make future value-creating acquisitions. It transforms a portion of Prestige's cash balance into a productive, income-generating asset.